Clinical Trials · NCT01886287

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

TerminatedPhase 2Octreotide (Prohibited)
Phase
Phase 2
Recruitment status
Terminated
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Enrollment
2
Start date
Dec 2013
Locations
1 site, United States
Primary endpoint
Number of Participants With Improved Frequency of Diarrhea
View Octreotide compound reference